Literature DB >> 12633575

Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia.

Uday Popat1, George Carrum, Helen E Heslop.   

Abstract

The majority of children and some adults with acute lymphocytic leukaemia (ALL) can be cured with current intensive chemotherapy regimens. For those patients who relapse or who do not achieve remission, allogeneic haemopoietic stem cell transplantation (HSCT) offers the best chance for long-term disease control. Different sources of haemopoietic stem cells including marrow, peripheral blood, and cord blood are now available and the introduction of subablative regimens has increased the number of patients who are transplant candidates. Relapse remains the major cause of transplant failure and immunotherapy strategies post-transplant to augment the graft versus leukaemia effect are being explored.

Entities:  

Mesh:

Year:  2003        PMID: 12633575     DOI: 10.1016/s0305-7372(02)00092-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  3 in total

1.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.

Authors:  Albert Oriol; Susana Vives; Jesús-María Hernández-Rivas; Mar Tormo; Inmaculada Heras; Concepción Rivas; Concepción Bethencourt; Federico Moscardó; Javier Bueno; Carlos Grande; Eloy del Potro; Ramon Guardia; Salut Brunet; Juan Bergua; Teresa Bernal; Maria-José Moreno; Carlota Calvo; Pilar Bastida; Evarist Feliu; Josep-Maria Ribera
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 2.  Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes.

Authors:  M Bemark; J Holmqvist; J Abrahamsson; K Mellgren
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Jerome Ritz; Edwin P Alyea; Joseph H Antin; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2007-11-26       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.